IRIS PubliCatt

De Sanctis, Roberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.383
NA - Nord America 1.278
AS - Asia 265
AF - Africa 20
SA - Sud America 6
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
Totale 2.957
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.261
IT - Italia 445
SE - Svezia 278
DE - Germania 221
IE - Irlanda 129
CN - Cina 94
SG - Singapore 65
FR - Francia 56
RU - Federazione Russa 52
GB - Regno Unito 43
IN - India 35
FI - Finlandia 26
UA - Ucraina 21
ES - Italia 16
CZ - Repubblica Ceca 15
TR - Turchia 15
IR - Iran 14
MK - Macedonia 12
BE - Belgio 11
NL - Olanda 11
CA - Canada 10
CI - Costa d'Avorio 10
RS - Serbia 9
EG - Egitto 8
HK - Hong Kong 8
CH - Svizzera 7
PL - Polonia 7
IL - Israele 6
JP - Giappone 6
RO - Romania 6
PA - Panama 5
PT - Portogallo 5
KR - Corea 4
SK - Slovacchia (Repubblica Slovacca) 4
AT - Austria 3
BR - Brasile 3
PH - Filippine 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AU - Australia 2
BT - Bhutan 2
HR - Croazia 2
PK - Pakistan 2
SA - Arabia Saudita 2
ZA - Sudafrica 2
AL - Albania 1
AR - Argentina 1
BD - Bangladesh 1
CL - Cile 1
CO - Colombia 1
DK - Danimarca 1
GL - Groenlandia 1
GR - Grecia 1
HU - Ungheria 1
KZ - Kazakistan 1
MX - Messico 1
MY - Malesia 1
QA - Qatar 1
TH - Thailandia 1
TW - Taiwan 1
VN - Vietnam 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 2.957
Salva come PNG Salva come JPEG
Città #
Chandler 323
Ashburn 197
Dublin 101
New York 84
Rome 78
Milan 76
San Mateo 38
Singapore 34
Marseille 33
Moscow 30
Princeton 28
Boston 26
Palermo 23
Ann Arbor 19
Los Angeles 19
Dearborn 18
Bremen 17
Wilmington 17
Houston 16
Helsinki 15
Nanjing 14
Nürnberg 14
Beijing 13
Brno 13
Cattolica 12
Pune 12
Augusta 11
Kish 11
Abidjan 10
Brussels 10
Jacksonville 10
Lancaster 10
Redwood City 10
Salamanca 10
Skopje 10
Bologna 9
Bari 8
Menlo Park 8
Seattle 8
Turin 8
Andover 7
Hebei 7
Shanghai 7
Woodbridge 7
Boardman 6
Izmir 6
Leawood 6
Niš 6
Redmond 6
Shenyang 6
Washington 6
Amsterdam 5
Cairo 5
Genoa 5
Lawrence 5
Munich 5
Norwalk 5
San Francisco 5
Stockholm 5
Toronto 5
Wandsworth 5
Bitonto 4
Brindisi 4
Changsha 4
Chicago 4
Fairfield 4
Fort Worth 4
Hong Kong 4
Jinan 4
Lisbon 4
Monza 4
Mountain View 4
Naaldwijk 4
Nanchang 4
Palagiano 4
Paris 4
Reggio Calabria 4
Caorle 3
Florence 3
Foggia 3
Grottaferrata 3
Guangzhou 3
Gunzenhausen 3
Istanbul 3
Jiaxing 3
Lappeenranta 3
Messina 3
Neded 3
Pulsano 3
Ronciglione 3
San Diego 3
Secaucus 3
Seoul 3
Spoleto 3
Abu Dhabi 2
Acquaviva Picena 2
Adelfia 2
Alexandria 2
Ancona 2
Ankara 2
Totale 1.650
Salva come PNG Salva come JPEG
Nome #
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy 253
Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module 209
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 106
Revised upper limb module for spinal muscular atrophy: Development of a new module 95
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience 84
Predominant distal muscle involvement in spinal muscular atrophy 80
Developmental milestones in type I spinal muscular atrophy 77
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 75
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 73
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study 72
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 69
Developmental milestones in type I spinal muscular atrophy 66
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 65
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 64
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 63
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 60
Longitudinal assessments in discordant twins with SMA 60
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 55
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 55
Assessing floppy infants: a new module 54
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 53
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 50
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 48
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 48
Nusinersen in type 0 spinal muscular atrophy: should we treat? 48
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 48
Clinical Variability in Spinal Muscular Atrophy Type III. 47
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 47
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 46
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 45
De novo partial 13q22-q34 trisomy with typical neurological and immunological findings: A case report with new genetic insights 45
Development of an academic disease registry for spinal muscular atrophy 45
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 41
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 40
Revised upper limb module for spinal muscular atrophy: 12 month changes 39
Reply to: The need for evidence-based treatment decisions in spinal muscular atrophy type 0 39
Point-of-care lung and diaphragm ultrasound in a patient with spinal muscular atrophy with respiratory distress type 1 39
Revised upper limb module for spinal muscular atrophy: Development of a new module 36
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 35
Risdiplam in Type 1 Spinal Muscular Atrophy 35
Longitudinal natural history of type I spinal muscular atrophy: A critical review 34
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? 32
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 32
Sleep disorders in spinal muscular atrophy 30
An observational study of functional abilities in infants, children, and adults with type 1 SMA 29
An observational study of functional abilities in infants, children, and adults with type 1 SMA 25
Needleless inhaled anesthesia with sevoflurane: Advantages of a simplified approach for children with spinal muscular atrophy undergoing intrathecal administration of nusinersen 24
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 21
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 18
Long term follow-up of scoliosis progression in type II SMA patients 18
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 18
An observational study of functional abilities in infants, children, and adults with type 1 SMA 17
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 16
Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study 16
Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool 14
Erratum: Long term natural history data in ambulant boys with duchenne muscular dystrophy: 36-month changes (PLoS ONE (2015) 10:12 (e0144079)) 13
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1) 12
Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World Data 11
Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients 10
Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test 7
Early treatment of type II SMA slows rate of progression of scoliosis 7
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 7
Ultrasound assessment of diaphragmatic function in type 1 spinal muscular atrophy 6
Totale 3.026
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.970
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.970
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020109 0 2 3 6 9 18 18 8 9 5 26 5
2020/202175 2 8 2 2 9 9 8 2 9 0 23 1
2021/2022398 13 6 5 72 28 11 9 63 26 19 73 73
2022/20231.124 99 149 65 158 76 138 70 98 157 19 54 41
2023/2024970 34 158 33 86 50 165 151 54 19 47 79 94
2024/202548 41 7 0 0 0 0 0 0 0 0 0 0
Totale 3.026